High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma

Blood

Volumn 105, Issue 7, 2005, Pages 2908-2915

  Björck, Erik ^b   Ek, Sara ^b   Landgren, Ola ^b   Jerkeman, Mats ^b   Ehinger, Mats ^b   Björkholm, Magnus ^b   Borrebaeck, Carl A K ^b   Porwit MacDonald, Anna ^a   Nordenskjöld, Magnus ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CELL CYCLE PROTEIN; CHLORAMBUCIL; CLADRIBINE; CYCLIN B1; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; KI 67 ANTIGEN; METHOTREXATE; MITOGUAZONE; ONCOPROTEIN; PREDNIMUSTINE; PREDNISONE; PROTEIN ANP32E; PROTEIN CDC2; PROTEIN CDKN3A; PROTEIN CKS1B; PROTEIN KIAA0101; RITUXIMAB; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL FUNCTION; DNA MICROARRAY; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; HUMAN TISSUE; MALE; METAPHASE; MITOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 15944429985     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2721     Document Type: Article

References (44)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
2. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454-1459.
3. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer. 2002;38:1167-1172.
4. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
5. Solal-Céligny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004. Prepublished on May 4, 2004, as DOI 10.1182/blood-2003-12-4434 (now available as Blood. 2004;104:1258-1265).
6. Solal-Céligny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004. Prepublished on May 4, 2004, as DOI 10.1182/blood-2003-12-4434 (now available as Blood. 2004;104:1258-1265).
7. Davidge-Pitts M, Dansey R, Bezwoda WR. Prolonged survival in follicular non Hodgkins lymphoma is predicted by achievement of complete remission with initial treatment: results of a long-term study with multivariate analysis of prognostic factors. Leuk Lymphoma. 1996;24:131-140.
8. Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 2003;101:2363-2367.
9. Zhao WL, Daneshpouy ME, Mounier N, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood. 2004;103:695-697.
10. Martinka M, Comeau T, Foyle A, Anderson D, Greer W. Prognostic significance of t(14:18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma. Clin Invest Med. 1997;20:364-370.
11. Møller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol. 1999;12:1010-1016.
12. Bilalovic N, Blystad AK, Golouh R, et al. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol. 2004;121:34-42.
13. Viardot A, Moller P, Hogel J, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol. 2002;20:4523-4530.
14. Höglund M, Sehn L, Connors JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004;39:195-204.
15. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484-1493.
16. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
17. Ek S, Björck E, Porwit-MacDonald A, Nordenskjöld M, Borrebaeck CA. Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica. 2004;89:686-695.
18. Ek S, Högerkorp CM, Dictor M, Ehinger M, Borrebaeck CA. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res. 2002;62:4398-4405.
19. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. WHO offset publication no. 48.
20. Affymetrix, Inc. Data analysis fundamentals. Available at: http://www.affymetrix.com/support/technical/manuals.affx. Accessed July 14, 2004.
21. Czader M, Mazur J, Pettersson M, et al. Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas. Cancer. 1996;77:1180-1188.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:157-181.
23. Cox D. Regression models and life tables. J Roy Stat Soc (B). 1972;34:187-202.
24. Bourne Y, Watson MH, Hickey MJ, et al. Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Cell. 1996;84:863-874.
25. Minshull J, Straight A, Rudner AD, Dernburg AF, Belmont A, Murray AW. Protein phosphatase 2A regulates MPF activity and sister chromatid cohesion in budding yeast. Curr Biol. 1996;6:1609-1620.
26. Gyuris J, Golemis E, Chertkov H, Brent R. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell. 1993;75:791-803.
27. Schrader C, Meusers P, Brittinger G, et al. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia. 2004;18:1200-1206.
28. Takahashi M, Yang XJ, Lavery TT, et al. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res. 2002;62:6598-6605.
29. Järvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
30. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood. 1997;89:601-609.
31. Escargueil AE, Plisov SY, Skladanowski A, et al. Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. FASEB J. 2001;15:2288-2290.
32. Fang G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell. 2002;13:755-766.
33. Martin-Lluesma S, Stucke VM, Nigg EA. Role of Heel in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2. Science. 2002;297:2267-2270.
34. Zur A, Brandeis M. Timing of APC/C substrate degradation is determined by fzy/fzr specificity of destruction boxes. EMBO J. 2002;21:4500-4510.
35. Rudner AD, Murray AW. Phosphorylation by Cdc28 activates the Cdc20-dependent activity of the anaphase-promoting complex. J Cell Biol. 2000;149:1377-1390.
36. Maxwell CA, Keats JJ, Crainie M, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell. 2003;14:2262-2276.
37. Mohapatra S, Yang X, Wright JA, Turley EA, Greenberg AH. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med. 1996;183:1663-1668.
38. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994;83:1460-1466.
39. Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 1995;85:3671-3678.
40. Llanos M, Alvarez-Arguelles H, Aleman R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol. 2001;18:15-22.
41. Wolowiec D, Berger F, Ffrench P, Bryon PA, Ffrench M. CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin's lymphomas. Leuk Lymphoma. 1999;35:147-157.
42. Jin YH, Park CK. Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications. J Korean Med Sci. 2002;17:322-327.
43. Juan G, Traganos F, James WM, et al. Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry. 1998;32:71-77.
44. de Vos S, Hofmann WK, Grogan TM, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest. 2003;83:271-285.